# Pizarra — PT-pseudo_1a4e0cf3b927 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_1a4e0cf3b927
Task: 1

Encounter: Urology - outpatient on 24 Feb 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 74-year-old male
  - PSA: 7.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.427 ng/mL²
  - PSA velocity: 1.15 ng/mL/yr
  - Prior PSA: 6.3 ng/mL
  - Prostate volume: 16.4 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8631027 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: Iodinated contrast (mild)
  - Additional notes: PSA 7 ng/mL. PI-RADS 5. PSAD 0.43. Prostate volume 16 mL. DRE nodus. csPCa 0.86.

Vitals: weight 84 kg, height 175 cm, BMI 27.4, BP 116/70 mmHg, HR 56 bpm. Smoking: Current smoker (37 pack-yr).

Chief complaint: Persistent elevation of prostate-specific antigen alongside a history of biopsy-confirmed malignancy prompted this clinical review.

History: A 74-year-old married tram driver who shares a home with his partner came to attention after routine primary care screening flagged a rising prostate-specific antigen level. He endorses mild lower urinary tract symptoms, tallying an IPSS of 6, characterized by slight nocturia and a weak stream, while explicitly denying pelvic pain or hematuria. Daily walks lasting 45 minutes sustain his activity level, and he abstains from alcohol entirely. A 37 pack-yr smoking history remains on record. Aside from a 2011 laparoscopic cholecystectomy, his medical background is clear. He notes occasional knee stiffness from prolonged standing on the tram platform, though swelling or inflammatory signs are absent. An Arabic interpreter will be present at our upcoming consultation to guarantee precise communication.

Physical examination: DRE — texture: firm, irregular Nodus (~1.5 cm) in the right lateral lobe; mobility: fixed; asymmetry: localized to the right, with the remainder of the gland maintaining symmetric architecture. General inspection reveals no abnormalities. Cardiovascular and respiratory auscultation are clear. Peripheral lymph nodes are non-palpable, and hepatosplenomegaly is absent. Vital signs register at 116/70 mmHg blood pressure and 56 beats per minute heart rate. Body mass index stands at 27.4 kg/m².

Patient info: tram driver; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Walking 45 min/day; IPSS score: 6/35 (mild LUTS).

Recent other appointments: Podiatry — routine foot care.
Admin: Interpreter (Arabic) requested for next visit.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.72 +/- 0.22   (95% CI 0.28-1.00)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.22  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.85 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'discuss': p +/- dp straddles 0.5. The classifier genuinely CANNOT tell the two answers apart here. Its number is a starting point only. Measured accuracy in this tier on the labelled cohort: 0.488 over 43 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the current mpMRI lesion size/zone compare against an earlier study?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend beyond the headline value?
  - previous_notes (get_previous_notes) -> What was the prior grade, surveillance pathway, and patient agreement?

This case hinges on the retrieved documents to determine if the prior positive biopsy status, combined with current imaging and PSA trajectory, warrants a re-biopsy or surveillance decision. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the specific clinical context of this patient, such as the PI-RADS 5 score, the rising PSA velocity (1.15 ng/mL/yr), and the prior positive biopsy status.
The prior could not weigh the specific combination of a high-risk imaging finding (PI-RADS 5) against a prior positive biopsy result, which is a critical point for re-biopsy decision-making.
The prior did not account for the specific PSA density (0.427 ng/mL²) or the specific PSA velocity (1.15 ng/mL/yr) in its calculation.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy with a high probability (0.72), but the guideline criterion explicitly states the visible panel is undetermined, meaning the prior's suggestion is based on insufficient data.
The prior's high probability (0.72 +/- 0.22) is in the 'discuss' tier, indicating the classifier genuinely cannot tell the two answers apart, suggesting the suggestion is highly unreliable for this specific patient profile.
The prior failed to account for the guideline's requirement that the decision must come from the retrieved documents, which it did not attempt to synthesize.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
psa_trend - What is the serial PSA trend beyond the headline value?
previous_notes - What was the prior grade, surveillance pathway, and patient agreement?
previous_notes - What was the prior grade, surveillance pathway, and patient agreement?

GUIDELINE ANCHOR
The guideline states that the decision must come from retrieved documents, specifically assessing if the prior grade is documented, if the lesion changed against a previous MRI, and if surveillance re-biopsy is due.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: Subject: Multiparametric MRI Prostate | Date: 12 February 2025 | Facility: Bravis Ziekenhuis. PI-RADS 5 lesion in the right mid-gland peripheral zone, highly suspicious for clinically significant prostate cancer. The lesion size is approximately 18 x 15 x 12 mm. This is a new finding compared to the prior biopsy bucket which was ISUP GG 2.

get_psa_trend
PSA trend: Shows a rising trajectory. Values include 3.1 (Mar 2022), 1.1 (Dec 2022), 5.6 (Sep 2023), 4.5 (May 2024), and 7.0 (Feb 2025). The velocity is increasing.

get_previous_notes
Previous notes: The most recent note from 29 Jun 2024 confirms a PSA of 6.3 ng/mL and mentions a urology follow-up was booked to review the persistent elevation and prior histological confirmation. The prior grade is not explicitly stated in these notes, only that a prior histological confirmation was pending review.

NOT RETRIEVED
laboratory_results
Laboratory results were not retrieved because the moderator's agenda did not require them, and the retrieved documents did not raise specific questions requiring this panel.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 5 lesion in the right mid-gland peripheral zone, highly suspicious for clinically significant prostate cancer.
- PSA trend: Rising trajectory, with the most recent value being 7.0 ng/mL and an increasing velocity.
- Previous notes: A urology follow-up was booked to review the persistent elevation and prior histological confirmation.

AGAINST sampling this patient now:
- Previous notes: The prior grade of the biopsy is not explicitly documented in the retrieved notes.

WHERE THIS LEANS
The evidence strongly suggests a need for further investigation due to the high-risk imaging finding (PI-RADS 5) and the rising PSA trend, which aligns with the statistical prior.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=abstains, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence (high-risk PI-RADS 5 lesion and rising PSA trend) strongly supports the need for further investigation, leading to a lean towards biopsy, despite the guideline criterion being undetermined initially.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision leans toward biopsy because the retrieved evidence showed a high-risk PI-RADS 5 lesion and a rising PSA trend, which aligns with the statistical prior. Although the guideline criterion was undetermined, the absence of a documented prior grade in the retrieved notes means the biopsy is necessary to establish the definitive diagnosis required for management planning. The statistical prior suggested biopsy with a probability of 0.72, which is accepted as a strong indicator when the retrieved data points toward further investigation.

Variables that carried weight: bx=important, age=important, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
